[Synergistic effect of new beta-lactam antibiotics, clavulanic acid and dibekacin on pathogenic microorganisms].
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D019818:Clavulanic Acid; D002969:Clavulanic Acids / Q000494:pharmacology*; D003982:Dibekacin / Q000494:pharmacology*; D004352:Drug Resistance, Microbial; D004357:Drug Synergism; D004755:Enterobacteriaceae / Q000187:drug effects*; D066298:In Vitro Techniques; D007612:Kanamycin / Q000031:analogs & derivatives*; D011550:Pseudomonas aeruginosa / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D002969:Clavulanic Acids; D019818:Clavulanic Acid; D003982:Dibekacin; D007612:Kanamycin
Synergiczne działanie nowych antybiotyków beta-laktamowych, kwasu klawulanowego i dibekacyny na drobnoustroje chorobotwórcze.